Patents Examined by Robin L. Teskin
  • Patent number: 4920211
    Abstract: A functional mutated E1A gene of human adenovirus subgroup B:1 is provided which has a modified autorepression functional domain that is effective to express E1A products that stimulate without net repression of promoters controlling an E1A mutated gene.
    Type: Grant
    Filed: January 4, 1988
    Date of Patent: April 24, 1990
    Assignee: Vanderbilt University
    Inventors: Clark Tibbetts, Pamela L. Larsen
  • Patent number: 4906474
    Abstract: A composition of matter suitable for implantation in the body to effect zero order drug release comprising a drug and a polymer of the formula: ##STR1## wherein R and R' can be the same or different and are hydrophobic organic linkages and n and m are integers of 1 or greater.
    Type: Grant
    Filed: May 21, 1984
    Date of Patent: March 6, 1990
    Assignee: Massachusetts Institute of Technology
    Inventors: Robert S. Langer, Howard Rosen, Robert J. Linhardt, Kam Leong
  • Patent number: 4894443
    Abstract: A novel class of polypeptides of the general formula (F-(Pro).sub.n).sub.m F, wherein F represents a flexible amino acid sequence wherein each amino acid is individually selected from the group consisting of serine, glycine, and threonine, and n is an integer from 4-8 inclusive and m is an integer from 1-4 inclusive, is disclosed. Thses polypeptides are useful in the construction of conjugates between antibodies and peptide toxins. The preparation of such conjugate toxins by linking antibodies to toxin/spacer composites prepared by recombinant techniques is also disclosed.
    Type: Grant
    Filed: September 7, 1984
    Date of Patent: January 16, 1990
    Assignee: Cetus Corporation
    Inventors: Lawrence I. Greenfield, Donald A. Kaplan, Danute E. Nitecki
  • Patent number: 4879226
    Abstract: A human physiologically active polypeptide, human Tumor Necrosis Factor (human TNF), comprising a specific amino acid sequence of 155 amino acid residues. The base sequence of the DNA coding for the human TNF has been determined using rabbit TNF cDNA. The human TNF can be advantageously produced on a large scale by recombinant DNA technique. The human TNF of the present invention has been found to be excellent in inducing necrosis of tumors with no toxic effect upon the normal tissues of the living body.
    Type: Grant
    Filed: April 6, 1984
    Date of Patent: November 7, 1989
    Assignee: Asahi Kasei Kogyo Kabushiki Kaisha
    Inventors: Robert B. Wallace, Hirataka Itoh
  • Patent number: 4873189
    Abstract: Hybrid cell lines which secret monoclonal antibody which is group-specific to bluetongue virus (BTV) antigen and which does not react to antigenically related epizootic hemorrhagic disease virus antigen are disclosed. The antibodies identify BTV in infected cell cultures with immunofluorescence and provide a means for ready diagnosis of BTV in animals.
    Type: Grant
    Filed: January 12, 1984
    Date of Patent: October 10, 1989
    Assignee: The United States of America as represented by the Secretary of Argriculture
    Inventors: Michael M. Jochim, Suzanne C. Jones
  • Patent number: 4871661
    Abstract: Materials can be screened for carcinogenic properties by administering them to test animals and assaying biological tissue, preferably plasma, for the presence of a 60K cancer-associated phosphoprotein. The test is applicable to a wide range of chemically-diverse carcinogens and is not restricted to carcinogens having one particular mode of action.
    Type: Grant
    Filed: June 18, 1985
    Date of Patent: October 3, 1989
    Assignee: The Ohio State University Research Foundation
    Inventors: Thomas E. Webb, Dorothy E. Schumm, Margaret Hanausek-Walaszek, Zbigniew Walaszek, Raymond W. Lang
  • Patent number: 4870053
    Abstract: A novel process for the preparation of water-soluble acyl glycoprotein extracted from Klebsiella Pneumoniae containing 30 to 45% by weight of proteins, 30 to 40% by weight of neutral saccharides, less than 4% of glucuronic acid, 2 to 5% by weight of osamines with a molecular weight of about 350,000 daltons and having a polysaccharide chain of n chains of one molecule of glucose and 4 molecules of galactose attached to an asparagine of a proteidic chain by a core formed of heptose and 2-keto-3-deoxy-octulosonic acid followed by an acyl portion containing .beta.-hydroxymyristic acid and then N-acetyl-glucosamine designated herein as F.sub.1 and compositions and a method of inducing antiallergic properties in warm-blooded animals.
    Type: Grant
    Filed: January 4, 1984
    Date of Patent: September 26, 1989
    Assignee: Roussel Uclaf
    Inventors: Rene Zalisz, Marie-France Salles
  • Patent number: 4867973
    Abstract: This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described.
    Type: Grant
    Filed: September 13, 1984
    Date of Patent: September 19, 1989
    Assignee: Cytogen Corporation
    Inventors: John W. F. Goers, Hurley D. King, Chyi Lee, Daniel J. Coughlin, Vernon L. Alvarez, John D. Rodwell, Thomas J. McKearn
  • Patent number: 4816563
    Abstract: Antigen specific excreted transfer factor may be obtained by collecting material, e.g. colostrum or milk, secreted by the mammary gland of a suitable lactating mammal, e.g. a cow having immunity to the antigen under suitable conditions such that materials which interfere with transfer factor efficacy are removed so as to obtain transfer factor. Colostrum or milk so collected may be used directly, typically after sterilization, or may be treated to further concentrate and/or purify transfer factor. Treatment to yield colostral whey containing transfer factor is presently the preferred method for obtaining transfer factor for use in conferring immunity against diseases associated with antigens for which the transfer factor is specific. Cell-associated transfer factor specific for an antigen may also be obtained by incubation release from, or lysis of, cells obtained from the collected material.
    Type: Grant
    Filed: November 15, 1984
    Date of Patent: March 28, 1989
    Assignee: Amtron, Inc.
    Inventors: Gregory B. Wilson, Gary V. Paddock
  • Patent number: 4808537
    Abstract: A method for isolating and cloning methanol inducible genes from Pichia is taught. The regulatory regions are useful for the methanol regulated expression of heterologous genes.
    Type: Grant
    Filed: October 30, 1984
    Date of Patent: February 28, 1989
    Assignee: Phillips Petroleum Company
    Inventors: David W. Stroman, Paul F. Brust, Steven B. Ellis, Thomas R. Gingeras, Michael M. Harpold, Juerg F. Tschopp
  • Patent number: 4797475
    Abstract: A composition of matter and method for using the composition of matter to isolate various cell elements from a heterogeneous cell suspension in a simple one step procedure. The composition is a monoclonal antibody mixture including complement and a non-toxic density gradient media. The composition provides a negative selection technique in which undesired subpopulation cells are lysed and separated from the desired cell subpopulation. The invention has particular application to isolation of white cell elements.
    Type: Grant
    Filed: July 17, 1985
    Date of Patent: January 10, 1989
    Assignee: The Regents of the University of California
    Inventors: Paul I. Terasaki, Jimmy Loon, Steven Hardiwidjaja, Nadim El-Awar
  • Patent number: 4792522
    Abstract: A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.
    Type: Grant
    Filed: August 22, 1985
    Date of Patent: December 20, 1988
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., Stanley W. Bray, James A. Bush, William T. Bradner
  • Patent number: 4789633
    Abstract: Liposomes containing phosphatidylethanolamine, palmitoyl homocysteine or oleic acid or palmitic acid, fuse rapidly when the pH of the medium is reduced below 7. Liposome fusion was measured by (a) mixing of the liposomal lipids as shown by resonance energy transfer, (b) gel filtration and (c) electron microscopy. The presence of phosphatidylethanolamine or acid addition esters thereof in the liposomes greatly enhances fusion; whereas the presence of phosphatidylcholine inhibits fusion. During fusion of liposomes containing phosphatidylethanolamine:palmitoyl homocysteine (8:2), almost all of the encapsulate calcein is released. Inclusion of cholesterol (40%) in the liposomes substantially decreases leakage without impairing fusion. Those pH sensitive liposomes are fused to deliver biologically active molecules such as DNA, into living cells.
    Type: Grant
    Filed: April 19, 1984
    Date of Patent: December 6, 1988
    Assignee: University of Tennessee Research Corporation
    Inventors: Leaf Huang, Jerome Connor
  • Patent number: 4788059
    Abstract: A vaccine for immunizing equines against strangles and a method of using the vaccine. The vaccine is made by isolating the causative organism Streptococcus equi (S. equi) from an abscess on a horse showing typical symptoms of strangles, and confirming the identity of the organism through standard biochemical techniques. The isolated S. equi is passed through a suitable growth medium (Todd-Hewitt broth) and two parts per million acriflavine hydrochloride is added. The acriflavine level is increased over a period of approximately eleven weeks to a concentration of about sixteen parts per million to yield an avirulent S. equi while retaining its antigenicity. The method of administering the vaccine consists of inoculating the horse intranasally with the attenuated S. equi.
    Type: Grant
    Filed: July 15, 1985
    Date of Patent: November 29, 1988
    Assignee: Coopers Animal Health, Inc.
    Inventor: Myron G. Usdin
  • Patent number: 4782023
    Abstract: An enzyme conjugate composition comprising an enzyme conjugate, a calcium salt and a polyethylene glycol is disclosed. The enzyme conjugate composition is effectively stabilized by the presence of the calcium salt and the polyethylene glycol.
    Type: Grant
    Filed: September 13, 1985
    Date of Patent: November 1, 1988
    Assignee: Abbott Laboratories
    Inventors: Mark A. Anawis, Roger E. Lindberg
  • Patent number: 4782021
    Abstract: This invention is a method of producing L-serine by causing glycine to react with formaldehyde by using the culture solution or the microbe cells of a microorganism belonging to the genus Escherichia, having the ability of producing serine hydroxymethyltransferase and not having the practical ability of producing L-serine from glycine alone or enzymatic matter obtained through the treatment of the above culture solution or microbe cells.In this invention, the yield of L-serine can be increased either by carrying out the reaction while maintaining aldehyde concentration at 20 mM or below or by using microbe cells of the aforementioned microorganism after they are caused to contact glycine.
    Type: Grant
    Filed: February 5, 1985
    Date of Patent: November 1, 1988
    Assignee: Mitsui Toatsu Chemicals, Inc.
    Inventors: Kenichi Ishiwata, Nobuyoshi Makiguichi, Hideki Kawashima, Tadashi Suzuki, Masami Imadegawa
  • Patent number: 4775630
    Abstract: A novel alteration of a viral DNA sequence, derived from a human adenovirus type 3 mutant (Ad3) designaed Ad3h15, provides a transcriptional control element which can be used to regulate expression of a selected gene in animal and human cells. The Ad3h15 control element blocks transcription of a controlled gene in the presence of the products of the Ad3 E1A gene, and amplifies transcription in the presence of type 5 (Ad5) adenovirus E1A gene products.
    Type: Grant
    Filed: August 15, 1986
    Date of Patent: October 4, 1988
    Assignee: Vanderbilt University
    Inventors: Clark Tibbetts, Pamela L. Larsen, Stephen N. Jones, Mary M. McGrane
  • Patent number: 4745064
    Abstract: The invention relates to a novel microorganism of the genus Rhodococcus, to the use thereof in a process for the microbiological degradation of amino-s-triazines and cyanuric acid in wastewaters, as well as to a process for the microbiological degradation of s-triazine derivatives to biomass or to degradation products such as NH.sup.30.sub.4 and/or chloride, which comprises the combined use of said microorganism with Pseudomonas spp.
    Type: Grant
    Filed: October 26, 1984
    Date of Patent: May 17, 1988
    Assignee: Ciba-Geigy Corporation
    Inventors: Alasdair M. Cook, Ralf Hutter
  • Patent number: 4742159
    Abstract: The present invention provides a process for the preparation of digitalis antibodies in which appropriate mammals are immunized with a digoxin bound to protein, the animal serum is obtained, the immune globulin-containing protein fraction is separated in known manner, the immunologically-active globulins are adsorbed on an immunologically-active column and separated from the other proteins, the antibodies are again eluted from the column and the Fab fractions are split with papain and purified, wherein, as immunologically-active adsorbent, there is used an inorganic matrix of large surface area to which digitoxin aldehyde is bound via a spacer which cannot be split with papain and the splitting off of the Fab fraction from the antibodies is carried out on the matrix.The present invention also provides digitalis antibodies obtained by this process, which antibodies can be used for the therapy of digitalis intoxications and for preparing immunological reagents for the determination of digitalis glycosides.
    Type: Grant
    Filed: December 19, 1983
    Date of Patent: May 3, 1988
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hans-Georg Batz, Herbert Jungfer, Helmut Lenz, Albert Roder
  • Patent number: 4672032
    Abstract: Methods are provided for the formation of dental enamel crystals in biosynthetic matrix form by the nucleation of calcium solutions with enamel proteins and for the use of such enamel crystals as restorative material.
    Type: Grant
    Filed: November 9, 1983
    Date of Patent: June 9, 1987
    Assignee: University of Southern California
    Inventors: Harold C. Slavkin, Malcolm L. Snead, Savio L. C. Woo, Margarita Zeichner-David